Literature DB >> 3400247

The economics of general thromboembolic prophylaxis.

D Bergqvist, S Jendteg, B Lindgren, T Mätzsch, U Persson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3400247     DOI： 10.1007/bf01655669

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  14 in total

1.  Management of heparin therapy: Controlled prospective trial.

Authors:  E W Salzman; D Deykin; R M Shapiro; R Rosenberg
Journal:  N Engl J Med       Date:  1975-05-15       Impact factor: 91.245

2.  Control and complications of intermittent heparin therapy.

Authors:  C S Norman; J L Provan
Journal:  Surg Gynecol Obstet       Date:  1977-09

3.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

4.  Heparin therapy in thromboembolic disease.

Authors:  R J Kernohan; C Todd
Journal:  Lancet       Date:  1966-03-19       Impact factor: 79.321

5.  Control of heparin therapy.

Authors:  W R Pitney; J E Pettit; L Armstrong
Journal:  Br Med J       Date:  1970-10-17

6.  Randomized prospective trial of continuous vs intermittent heparin therapy.

Authors:  R L Glazier; E B Crowell
Journal:  JAMA       Date:  1976-09-20       Impact factor: 56.272

7.  Deep venous insufficiency after postoperative thrombosis diagnosed with 125I-labelled fibrinogen uptake test.

Authors:  A Lindhagen; D Bergqvist; T Hallböök
Journal:  Br J Surg       Date:  1984-07       Impact factor: 6.939

8.  Heparin and the in-hospital management of deep venous thrombosis: cost considerations.

Authors:  T W Rooke; P J Osmundson
Journal:  Mayo Clin Proc       Date:  1986-03       Impact factor: 7.616

9.  Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding.

Authors:  H A Holm; U Abildgaard; S Kalvenes
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

10.  Haemorrhagic complications of heparin therapy.

Authors:  M J Mant; B D O'Brien; K L Thong; G W Hammond; R V Birtwhistle; M G Grace
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321
View more
  9 in total

1.  Current use of thromboembolism prophylaxis for laparoscopic cholecystectomy patients in Sweden.

Authors:  F Lindberg; M Bjorck; I Rasmussen; D Bergqvist
Journal:  Surg Endosc       Date:  2004-12-02       Impact factor: 4.584

Review 2.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

3.  Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective.

Authors:  L C Borris; M R Lassen
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Prophylaxis for venous thromboembolism in hip fracture surgery: total costs and cost effectiveness in The Netherlands.

Authors:  W E Mol; T C Egberts
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

Review 5.  Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.

Authors:  D R Anderson; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 6.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 7.  Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.

Authors:  L A Levin; D Bergqvist
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis.

Authors:  C A Estrada; C J Mansfield; G R Heudebert
Journal:  J Gen Intern Med       Date:  2000-02       Impact factor: 5.128

9.  Multicentre hospital drug utilization study on the prophylaxis of venous thromboembolism. The Venous Thromboembolism Study Group of the Spanish Society of Clinical Pharmacology.

Authors:  J A Vallès; A Vallano; F Torres; J M Arnau; J R Laporte
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.